One of the most significant milestones during the second quarter was Inify becoming officially operational in the UK.
With our UK laboratory completed and CQC approval secured, Inify signed an agreement with University Hospitals Plymouth NHS Trust in June. The laboratory has since begun receiving patient samples.
In this panel talk, CEO Fredrik Palm and COO Emelie Edvigsson discuss the journey behind the UK launch, what this milestone means for Inify and the opportunities ahead.
Watch the full conversation here.
For further information, please contact CEO Fredrik Palm, fredrik.palm@inify.com or visit https//www.inify.com.
Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis. The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.
Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.
Inify Laboratories is an international group headquartered in Solna, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.